Objective: To evaluate the efficacy and safety of tubeless mini-percutaneous nephrolithotomy (mini-PCNL) for the management of large (>20 mm) renal stones. Materials and Methods: Hospital based retrospective study which analysed 110 consecutive adult patients who underwent tubeless mini-PCNL for large renal stones between January 2023 to January 2024 in the department of Urology. Data on demographics, stone characteristics, operative parameters, and outcomes were collected. Stone-free status was assessed within 2 weeks postoperatively using X-ray or noncontrast computed tomography (NCCT). Complications were recorded using the Clavien-Dindo classification, and statistical analysis identified predictors of residual fragments. Results: The mean stone size was 28.3 ± 5.6 mm, and single-tract access was achieved in 92% of cases. The mean operative time was 82.5 ± 15.4 minutes, and the overall stone-free rate was 88%. Residual fragments (<4 mm) were observed in 12% of patients. The complication rate was 13.6%, with most classified as minor (Clavien-Dindo Grades I and II). The mean hospital stay was 2.8 ± 1.2 days, with no major complications (Grade IV or V) reported. Higher Guy’s stone scores and larger stone sizes were significant predictors of residual fragments (p<0.05). Conclusion: Tubeless mini-PCNL is an effective and safe treatment option for large renal stones, achieving high stone-free rates with minimal morbidity and reduced hospital stays. Its minimally invasive nature and favorable outcomes make it a promising alternative to standard PCNL, particularly for appropriately selected patients.